Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News PAVmed Inc PAVM

Alternate Symbol(s):  PAVMZ

Healthcare Medical Devices
PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates through three lines of business: Medical Devices, Diagnostics, and Digital Health. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device... see more

Recent & Breaking News (NDAQ:PAVM)

PAVmed's PortIO(TM) Intraosseous Infusion System Achieves Multiple Milestones

GlobeNewswire November 7, 2019

PAVmed to Hold Business Update Conference Call on November 21, 2019

GlobeNewswire November 6, 2019

PAVmed Secures Financing up to $14 Million for Advancement of its Lead Products to Commercialization

GlobeNewswire November 5, 2019

PAVmed Reports Second Quarter 2019 Financial Results and Provides Business Update

GlobeNewswire September 5, 2019

USPTO Grants PAVmed Patent Covering its CarpX(TM) Device

GlobeNewswire August 21, 2019

PAVmed Successfully Completes Clinical Safety Study Procedures for CarpX(TM) 510(k) Re-submission

GlobeNewswire August 15, 2019

PAVmed to Hold Business Update Conference Call on September 5, 2019

GlobeNewswire August 7, 2019

PAVmed to Join Russell Microcap® Index

GlobeNewswire June 26, 2019

PAVmed Subsidiary Lucid Diagnostics Receives FDA 510(k) Clearance for EsoCheck(TM)

GlobeNewswire June 24, 2019

PAVmed Reports First Quarter 2019 Financial Results and Provides Business Update

GlobeNewswire May 21, 2019

PAVmed Announces First Human CarpX(TM) Procedures

GlobeNewswire May 20, 2019

PAVmed to Hold Business Update Conference Call on May 21, 2019

GlobeNewswire May 6, 2019

PAVmed Reports Excellent DisappEAR(TM) Animal Study Results

GlobeNewswire April 24, 2019

PAVmed to Hold Business Update Conference Call on April 4, 2019

GlobeNewswire March 21, 2019

PAVmed Announces NextFlo™ Breakthrough

GlobeNewswire March 20, 2019

PAVmed Announces PortIO™ Breakthrough

GlobeNewswire March 13, 2019

PAVmed Subsidiary Lucid Diagnostics Launches World-Class Medical Advisory Board and Appoints Chief Medical Officer

GlobeNewswire February 28, 2019

PAVmed Provides Business Update

GlobeNewswire January 10, 2019

PAVmed Subsidiary Lucid Diagnostics Files 510(k) Submission with FDA for EsoCheck™ Cell Collection Device

GlobeNewswire November 29, 2018

Consolidated Research: 2018 Summary Expectations for Moleculin Biotech, Novan, PAVmed, Maui Land & Pineapple, Hallmark Financial Services, and McEwen Mining — Fundamental Analysis, Key Performance Indications

GlobeNewswire November 19, 2018